Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Amgen Inc (AMGN) AI Forecast

Our AI ranks Amgen Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Free account • 30-day free trial

$AMGN Bearish Signal Full forecast available

Amgen Inc (AMGN) Stock Forecast Sept. 21, 2026


Amgen Inc (AMGN) AI Stock Price Forecast & Investment Analysis

Amgen Inc Stock Price Chart and Technical Analysis

Loading chart...

Amgen Inc (AMGN) - Comprehensive Stock Analysis & Investment Research

Deep dive into Amgen Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 21, 2026 (UTC)

Amgen Inc Investment Summary

When evaluating whether Amgen Inc (AMGN) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Amgen Inc (AMGN) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $213 billion, the company is classified as a mega-cap stock, typically characterized by high stability and strong institutional backing.

Financial Performance Analysis

Our comprehensive financial analysis covers Amgen Inc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Amgen Inc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Amgen Inc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Amgen Inc

Sign Up Free
Corporate Identity

Amgen Inc (Stock Symbol: AMGN) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Amgen Inc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Amgen Inc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Amgen Inc...

Unlock Full Company Profile

Get complete details about Amgen Inc

Sign Up Free
Revenue & Growth Analysis

Amgen Inc generates annual revenues of $38 billion , demonstrating substantial market presence and operational scale.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Amgen Inc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Amgen Inc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Amgen Inc...

Unlock Financial Analysis

Get complete financial metrics for Amgen Inc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Amgen Inc's AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Amgen Inc strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mega-cap market leader, the company commands significant market influence, enjoying substantial competitive moats including brand recognition, scale economies, and extensive distribution networks. Mega-cap status typically brings advantages in capital access, talent acquisition, and partnership opportunities, while also attracting the highest levels of institutional investor and analyst coverage.

Industry Competitive Landscape

Amgen Inc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company demonstrates exceptional operational efficiency through free cash flow generation of $10 billion annually , with year-over-year cash flow growth of 3.9%. This substantial cash generation capability provides significant strategic flexibility for acquisitions, share repurchases, dividend growth, or debt reduction—all while maintaining operational investments necessary to defend market position.

Margin & Pricing Power Analysis

The company maintains a 69.5% gross margin which reflects strong pricing power and/or low direct production costs relative to revenue. Gross margins are only comparable within an industry, so read this level against the company's peers rather than the market as a whole.

Operating margin of 30.0% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. This strong operating margin indicates excellent cost control and efficient organizational structure relative to the revenue base.

Asset Utilization Efficiency

Asset turnover ratio of 0.40x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 1.37 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Amgen Inc (AMGN) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Amgen Inc stock analysis.

Deep dive into Amgen Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Amgen Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Amgen Inc: With a P/E ratio of 24.31, the market moderately values the company's earnings.

P/E Ratio 24.31x
P/B Ratio 18.19x
Market Cap $212.55B
Dividend Yield 2.49%
EPS $16.09
Book Value/Share $21.62
Revenue/Share $70.46
FCF/Share $18.82
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Amgen Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Amgen Inc: An ROE of 74.8% demonstrates excellent shareholder value creation.

ROE 74.8%
ROA 9.1%
ROIC 16.3%
Gross Margin 69.5%
Operating Margin 30.0%
Net Margin 23.0%
EBT Margin 27.0%
Tax Rate 15.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Amgen Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Amgen Inc: A current ratio of 1.37 shows adequate liquidity.

Current Ratio 1.37x
Quick Ratio 1.13x
D/E Ratio 7.18x
Financial Leverage 8.18x
Interest Coverage 5.2x
Working Capital $9.46B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Amgen Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Amgen Inc: Free cash flow of $10175M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $12.48B
Free Cash Flow $10.18B
Capital Spending -$2.30B
OCF Growth YoY 3.9%
FCF Growth YoY -4.1%
FCF/Sales 26.7%
CapEx/Sales 6.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Amgen Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Amgen Inc: An asset turnover of 0.40x suggests room for improvement in asset utilization.

Asset Turnover 0.40x
Receivables Turnover 3.7x
Inventory Turnover 1.9x
Fixed Assets Turnover 4.5x
Days Sales Outstanding 98 days
Days Inventory 196 days
Payables Period 90 days
Cash Conversion Cycle 203 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Amgen Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Amgen Inc: With annual revenue of $38095M, Amgen Inc operates at significant scale.

Income Statement
Total Revenue $38.09B
Operating Income $11.43B
Net Income $8.74B
R&D Expense $7.63B
SG&A Expense $7.02B
Cost of Goods Sold $11.61B
Balance Sheet Highlights (USD millions)
Total Current Assets $34.96B (36.6% of assets)
Cash & Short-term Investments $13.99B (14.6% of assets)
Accounts Receivable $10.23B (10.7% of assets)
Inventory $6.22B (6.5% of assets)
Total Liabilities $83.95B (87.8% of assets)
Short-term Debt $22.64B (23.7% of assets)
Dividend & Shareholder Information
Dividends Per Share $9.78
Payout Ratio 60.8%
Shares Outstanding 541M

Latest Amgen Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Amgen Inc (AMGN) stock price and investment outlook.

More news available

Sign up free to read all 10 news articles and stay updated on market developments.

Sign Up Free to Read More

Where AMGN sits on the market map

Explore the map →

Amgen Inc Industry Peers - Biological Products, (No Diagnostic Substances)

Companies classified under the same SEC industry code as Amgen Inc (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
AMGN ██% $212.55B 24.3x 18.2x
GILD ██% $186.13B x 15.7x
MRNA ██% $61.50B x 9.1x
ARGX ██% $61.15B x x
RVMD ██% $40.93B x 15.7x
BIIB ██% $32.34B 23.6x 1.7x
BNTX ██% $24.78B x x
MESO ██% $19.62B x x
NBIX ██% $14.86B 21.1x 4.0x
EXEL ██% $14.18B x 7.7x
HALO ██% $12.76B 30.9x 88.9x
TECH ██% $11.35B 62.4x 5.4x
TWST ██% $10.47B x 23.5x
APGE ██% $10.22B x x
RGEN ██% $9.98B 240.3x 4.7x
KRYS ██% $9.97B 41.3x 7.3x
KYMR ██% $9.79B x 6.5x
QGEN ██% $9.40B x 2.5x
IBRX ██% $8.99B x x
PCVX ██% $8.65B x 3.1x
IMVT ██% $7.63B x 10.4x
CGON ██% $6.94B x 6.7x
SRRK ██% $5.68B x 22.4x
CRSP ██% $5.64B x 3.2x
IOVA ██% $4.64B x 6.3x
ADPT ██% $4.45B x 31.1x
RLAY ██% $4.13B x 4.6x
DBVT ██% $3.58B x 21.2x
TARS ██% $3.43B x 9.9x
DNLI ██% $3.27B x 3.9x
BEAM ██% $2.61B x 2.4x
BCRX ██% $2.24B x x
SCNI ██% $2.16B x 275.4x
ADMA ██% $2.13B 12.6x 5.2x
KOD ██% $2.06B x 33.7x
RXRX ██% $2.05B x 2.2x
VCEL ██% $2.05B 84.6x 5.5x
ALVO ██% $1.83B x x
VIR ██% $1.79B x 1.8x
COAG ██% $1.77B x 3.9x
NVAX ██% $1.67B x x
IMCR ██% $1.65B x 3.9x
TSHA ██% $1.64B x 4.2x
CGEM ██% $1.37B x 4.3x
MGTX ██% $1.27B 16.1x 5.9x
VOR ██% $1.27B x x
MAZE ██% $1.25B x 2.8x
REPL ██% $1.23B x 11.7x
JATT ██% $1.17B x 6.0x
ODTX ██% $1.17B x 2.8x
IMTX ██% $1.16B x x
VALN ██% $1.14B x x
GLUE ██% $1.03B x 2.1x
SLDB ██% $955M x 2.6x
SANA ██% $928M x 6.0x
CADL ██% $858M x 6.8x
FDMT ██% $841M x 2.1x
AURA ██% $660M x 2.1x
ALLO ██% $584M x 1.3x
PRME ██% $566M x 14.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Amgen Inc Stock Forecast

How accurate are Amgen Inc stock predictions?

A per-ticker accuracy statistic for AMGN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Amgen Inc stock price forecasts?

Our analysis considers Amgen Inc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Amgen Inc a good investment in 2026?

Based on our AI analysis, Amgen Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Amgen Inc forecasts updated?

Amgen Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 21, 2026.

Want a simpler view of Amgen Inc?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...